CytomX Therapeutics (NASDAQ:CTMX) Upgraded to Buy at StockNews.com
StockNews.com upgraded shares of CytomX Therapeutics (NASDAQ:CTMX – Free Report) from a hold rating to a buy rating in a research report released on Monday. A number of other equities analysts have also commented on the company. Wedbush reissued an “outperform” rating and set a $5.00 price target on shares of CytomX Therapeutics in a […]
StockNews.com upgraded shares of CytomX Therapeutics (NASDAQ:CTMX – Free Report) from a hold rating to a buy rating in a research report released on Monday. A number of other equities analysts have also commented on the company. Wedbush reissued an “outperform” rating and set a $5.00 price target on shares of CytomX Therapeutics in a […]
